NMPA Approves Ambroxol Hydrochloride Oral Drops for Over-the-Counter Sale
China’s National Medical Products Administration (NMPA) has approved the switch of ambroxol hydrochloride oral drops...
Fineline Cube
Biogen’s Zurzuvae Receives Positive CHMP Opinion for Postpartum Depression Treatment
US-based Biogen (NASDAQ: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP)...
GSK’s Blenrep Approved in EU for Relapsed or Refractory Multiple Myeloma
UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced today that Blenrep has received European Union (EU) approval...
Sanofi’s Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma
France-based Sanofi (NASDAQ: SNY) announced that the European Commission has approved its anti-CD38 monoclonal antibody...
Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials
Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing...
Matchpoint Therapeutics Partners with Novartis to Develop Oral Covalent Inhibitors for Inflammatory Diseases
Matchpoint Therapeutics, a privately held biotechnology company based in Watertown, Massachusetts, announced an exclusive option...
SinoCellTech’s SCT640C Injection Receives NMPA Approval for RA Clinical Trials
China-based SinoCellTech Group Ltd (SHA: 688520) announced today that its self-developed product, SCT640C injection, has...
Hengrui Pharmaceuticals’ HRS8179 and HRS-1893 Receive NMPA Clinical Trial Approval
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced today that it has received clinical...
Cryofocus Medtech’s Asthma Cryoablation System Granted FDA Breakthrough Device Designation
China-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) announced today that its self-developed asthma cryoablation...
3Sbio and Pfizer Finalize Licensing Agreement for PD-1/VEGF Bispecific Antibody SSGJ-707
China-based 3Sbio Inc. (HKG: 1530) announced today that its global licensing agreement with Pfizer Inc.,...
Roche AG Reports 7% Sales Growth in H1 2025, Driven by Pharmaceuticals Expansion
Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced its H1 2025 financial results, reporting...
GenFleet Therapeutics Announces Fast Track Designation for GFH375/VS-7375 in Pancreatic Cancer
China-based GenFleet Therapeutics announced on July 25, 2025, that its oral KRAS G12D inhibitor, GFH375/VS-7375,...
Leads Biolabs Lists on Hong Kong Stock Exchange in $189 Million IPO
China-based Leads Biolabs (HKG: 9887) officially listed on the Main Board of the Hong Kong...
Everest Medicines Completes HK$1.57 Billion Share Placement to Advance R&D and Commercialization
China-based Everest Medicines (HKG: 1952) announced today the completion of a share placement of 22,561,000...
Yangtze River Pharmaceutical’s Tadalafil Hydrochloride Tablets Approved for ED Treatment in China
China-based Yangtze River Pharmaceutical Group announced on July 25, 2025, that its Class 1 innovative...
Ipsen’s Cabometyx Approved by European Commission for Neuroendocrine Tumors
France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that its anticancer drug Cabometyx...
NHSA Announces Reforms to Centralized Drug Procurement Policies Beyond Lowest Price
The National Healthcare Security Administration (NHSA) held a press conference today on the “High-Quality Completion...
Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025
Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group...
Kelun-Biotech’s SKB378/WIN378 Enters Global Phase II Trial for Asthma Treatment
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced on July 23, 2025, that its partner...
Sirius Therapeutics’ SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases
China-based Sirius Therapeutics announced on July 23, 2025, that its next-generation siRNA therapy, SRSD107, has...